About: Update in the treatment of non-influenza respiratory virus infection in solid organ transplant recipients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Update in the treatment of non-influenza respiratory virus infection in solid organ transplant recipients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Update in the treatment of non-influenza respiratory virus infection in solid organ transplant recipients
Creator	Clark, Nina Reid, Gail Grim, Shellee
Source	Medline; PMC
abstract	Introduction: Despite the improved outcomes in solid organ transplantation with regard to prevention of rejection and increased patient and graft survival, infection remains a common cause of morbidity and mortality. Respiratory viruses are a frequent and potentially serious cause of infection after solid organ transplantation. Furthermore, clinical manifestations of respiratory virus infection (RVI) may be more severe and unusual in solid organ transplant recipients (SOTRs) compared with the non-immunocompromised population. Areas covered: This article reviews the non-influenza RVIs that are commonly encountered in SOTRs. Epidemiologic and clinical characteristics are highlighted and available treatment options are discussed. Expert opinion: New diagnostic tools, particularly rapid molecular assays, have expanded the ability to identify specific RVI pathogens in SOTRs. This is not only useful from a treatment standpoint but also to guide infection control practices. More data are needed on RVIs in the solid organ transplant population, particularly regarding their effect on rejection and graft dysfunction. There is also a need for new antiviral agents active against these infections as well as markers that can identify which patients would most benefit from treatment.
has issue date	2017-04-28(xsd:dateTime)
bibo:doi	10.1080/14656566.2017.1322063
bibo:pmid	28425766
has license	no-cc
sha1sum (hex)	7f7940bc0ca1e198694f7258fb08f8bf0fe1ed3a
schema:url	https://doi.org/10.1080/14656566.2017.1322063
resource representing a document's title	Update in the treatment of non-influenza respiratory virus infection in solid organ transplant recipients
has PubMed Central identifier	PMC7103702
has PubMed identifier	28425766
schema:publication	Expert Opin Pharmacother
resource representing a document's body	covid:7f7940bc0ca1e198694f7258fb08f8bf0fe1ed3a#body_text
is schema:about of	named entity 'INFECTION IN SOLID ORGAN TRANSPLANT RECIPIENTS' named entity 'UPDATE' named entity 'RESPIRATORY VIRUS INFECTION' named entity 'INFLUENZA' named entity 'NON-' named entity 'TREATMENT' named entity 'LRTI' named entity 'pathogens' named entity 'self-limited' named entity 'adverse effects' named entity 'RSV infection' named entity 'lung transplant' named entity 'Middle East respiratory syndrome coronavirus' named entity 'pathogens' named entity 'Immunocompromised patients' named entity 'sensitivity and specificity' named entity 'AdV' named entity 'immunotherapy' named entity 'lung transplant' named entity 'cytokines' named entity 'epidemiology' named entity 'viruses' named entity 'AdV' named entity 'cidofovir' named entity 'methylprednisolone' named entity 'lung transplant' named entity 'liver' named entity 'HRV' named entity 'paramyxovirus' named entity 'RSV' named entity 'severe infections' named entity 'immunosuppressive therapy' named entity 'lung transplant' named entity 'aerosolized' named entity 'phase 2' named entity 'transplant recipients' named entity 'serology' named entity 'hemolysis' named entity 'URTI' named entity 'aerosolized' named entity 'infection' named entity 'LRTI' named entity 'RSV' named entity 'infection' named entity 'aspirate' named entity 'antiviral therapy' named entity 'molecular diagnostics' named entity 'dyspnea' named entity 'respiratory failure' named entity 'picornaviruses' named entity 'stages of development' named entity 'asthma' named entity 'statistically significant' named entity 'FDA' named entity 'hypogammaglobulinemia' named entity 'interferon-α' named entity 'allograft' named entity 'supportive care' named entity 'RSV' named entity 'IVIG' named entity 'heart transplant' named entity 'viral proteins' named entity 'single-stranded RNA' named entity 'prophylaxis' named entity 'acute rejection' named entity 'hand, foot, and mouth disease' named entity 'RSV infection' named entity 'vaccines' named entity 'RSV' named entity 'LRTI' named entity 'aerosolized' named entity 'substrates' named entity 'HRV' named entity 'immunotherapies' named entity '7.5' named entity 'Human coronaviruses' named entity 'nausea' named entity 'infection' named entity 'enteroviruses'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software